Left Ventricular Outflow Tract Obstruction (LVOTO)
Definition
Left ventricular outflow tract obstruction (LVOTO) is a dynamic obstruction to LV systolic outflow caused primarily by systolic anterior motion (SAM) of the mitral valve leaflet contacting the interventricular septum. It is present in ~70% of HCM patients (resting or provocable) and is a major cause of symptoms and a contributor to SCD risk. LVOTO is defined by a peak instantaneous Doppler gradient ≥30 mmHg; the threshold for pharmacological and invasive treatment is ≥50 mmHg.
Key Concepts
Assessment
- Assessment protocol (Class I, Level B): 2D Doppler echo at rest + Valsalva manoeuvre (sitting, semi-supine; then standing if no gradient provoked). If symptomatic and resting/Valsalva gradient <50 mmHg: exercise stress echocardiography. (sources/esc-cmp-2023)
- LVOTO ≥30 mmHg = obstruction; ≥50 mmHg = haemodynamically significant (treatment threshold). (sources/esc-cmp-2023)
- Pharmacological provocation (dobutamine) is not advised — not physiological, poorly tolerated. (sources/esc-cmp-2023)
- Transoesophageal echocardiography for mechanism clarification before invasive procedures. (sources/esc-cmp-2023)
Pharmacological Management (stepwise)
- Non-vasodilating beta-blockers (first-line, Class I, Level B) — titrated to maximum tolerated dose.
- Verapamil or diltiazem (Class I, Level B) — if beta-blockers contraindicated or ineffective.
- Disopyramide added to beta-blockers (Class I, Level B) — QTc monitoring required (reduce if >500 ms).
- Mavacamten (Class IIa, Level A) — considered when above therapy is insufficient; echocardiographic surveillance of LVEF required. (sources/esc-cmp-2023)
- Agents to avoid: digoxin, nitrates, phosphodiesterase inhibitors (all may exacerbate LVOTO). (sources/esc-cmp-2023)
- Low-dose diuretics may cautiously improve exertional dyspnoea (Class IIb, Level C); hypovolaemia must be avoided. (sources/esc-cmp-2023)
Invasive Management
- Indication: LVOTO ≥50 mmHg + NYHA III–IV symptoms refractory to maximal drug therapy. (sources/esc-cmp-2023)
- Two options: surgical myectomy and alcohol septal ablation (ASA). See concepts/Septal-Reduction-Therapy.
- Asymptomatic LVOTO: no indication for invasive procedures; pharmacological treatment may be considered in selected cases (Class IIb). (sources/esc-cmp-2023)
AHA 2024 Algorithm Differences (vs ESC 2023)
- AHA 2024 Step 3 options (all Class I, Level B-R): myosin inhibitor (adults only), OR disopyramide + AV nodal blocker, OR SRT — elevating mavacamten to Class I (ESC 2023 positions mavacamten as Class IIa, step 4 below disopyramide). (sources/HCM-AHA-2024)
- Verapamil — Class III: Harm in patients with severe dyspnea at rest, hypotension, very high resting gradients (>100 mmHg), or children <6 weeks of age. (sources/HCM-AHA-2024)
- Vasodilators and digoxin: discontinuation reasonable in symptomatic obstructive HCM as they can worsen LVOTO (Class IIb). (sources/HCM-AHA-2024)
- Dynamic nature: gradients vary with heart rate, BP, volume, activity, medications, food, and alcohol intake. Dobutamine provocation not advised (not specific, not physiologic). (sources/HCM-AHA-2024)
- SRT eligibility criteria (AHA 2024): (a) severe dyspnea/chest pain usually NYHA III–IV, (b) peak LVOT gradient ≥50 mmHg at rest or with physiologic provocation + SAM, (c) sufficient anterior septal thickness for the procedure. (sources/HCM-AHA-2024)
Invasive Hemodynamic Assessment of LVOTO
- Pressure contour analysis: Dynamic LVOTO → spike-and-dome aortic contour (rapid initial upstroke at AV opening, then late systolic pressure drop as obstruction develops) + late-peaking LV pressure; fixed valvular obstruction → parvus et tardus aortic upstroke from time of AV opening sources/hemodynamics-circ-2012
high - Braunwald-Brockenborough sign: On the post-PVC beat, HCM with dynamic LVOTO shows a decrease in aortic pulse pressure (enhanced obstruction from post-extrasystolic potentiation); fixed valvular AS shows an increase in pulse pressure — key diagnostic differentiator in the cath lab sources/hemodynamics-circ-2012
high - Isoproterenol provocation: When Valsalva and PVC induction fail to provoke a gradient ≥50 mmHg, isoproterenol infusion (β1+β2 stimulation) simulates exercise and can unmask labile outflow obstruction before septal ablation; also used post-ablation to confirm adequate gradient reduction sources/hemodynamics-circ-2012
high - Technical caution in HCM cath lab: Catheters frequently entrap in hypertrophied hyperdynamic ventricles → erroneous pressure measurements; transseptal approach preferred; if retrograde catheter used, multipurpose/Rodriquez catheter (distal side holes) preferred over long-sidehole pigtail catheters sources/hemodynamics-circ-2012
high - Note: dobutamine provocation is NOT advised for routine LVOTO assessment by ESC/AHA guidelines (not physiological, poorly tolerated); however, dobutamine is used for the distinct purpose of distinguishing true vs pseudo-aortic stenosis in low-flow/low-gradient states sources/esc-cmp-2023
very highsources/HCM-AHA-2024very high
Contradictions / Open Questions
- Mavacamten positioning — AHA Class I vs. ESC Class IIa: AHA 2024 elevates mavacamten to a Class I step-3 option equivalent to disopyramide or SRT. ESC 2023 positions mavacamten as Class IIa, step 4 — below disopyramide and only after it has failed or is not tolerated. No head-to-head trial comparing mavacamten directly to disopyramide or SRT exists. The two different tiers reflect committee interpretation of the same EXPLORER and VALOR trial data. (sources/HCM-AHA-2024, sources/esc-cmp-2023)
- Verapamil — Class III in specific scenarios (AHA) vs. Class I (ESC): AHA 2024 designates verapamil as Class III: Harm in HCM patients with severe dyspnea at rest, hypotension, very high resting gradients (>100 mmHg), or children <6 weeks. ESC 2023 lists verapamil/diltiazem as Class I second-line for LVOTO. The same drug is simultaneously Class I (ESC) and contraindicated in specific HCM phenotypes (AHA), creating discordant guidance for the same patients. (sources/HCM-AHA-2024, sources/esc-cmp-2023)
Connections
- Related to entities/HCM
- Related to entities/Mavacamten
- Related to concepts/Septal-Reduction-Therapy
- Related to concepts/HCM-Risk-SCD